Campylobacter Abundance in Breastfed Infants and Identification of a New Species in the Global Enterics Multicenter Study

Xiaoming Bian, a,b Jolene M. Garber, a,b Kerry K. Cooper, c Steven Huynh, d Jennifer Jones, e Michael K. Mills, b Daniel Rafala, b Dilruba Nasrin, e Karen L. Kotloff, e Craig T. Parker, d Sharon M. Tennant, e William G. Miller, d Christine M. Szymanski a,b

a Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA
b Department of Microbiology, University of Georgia, Athens, Georgia, USA
c School of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, Arizona, USA
d Produce Safety and Microbiology Research Unit, Agricultural Research Service, U.S. Department of Agriculture, Albany, California, USA
e Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA

ABSTRACT Campylobacter jejuni is a leading cause of bacterial diarrhea worldwide and is associated with high rates of mortality and growth stunting in children inhabiting low- to middle-resource countries. To better understand the impact of breastfeeding on Campylobacter infection in infants in sub-Saharan Africa and South Asia, we examined fecal microbial compositions, bacterial isolates, and their carbohydrate metabolic pathways in Campylobacter-positive infants <1 year of age from the Global Enterics Multicenter Study. Exclusively breastfed infants with diarrhea exhibited high Campylobacter abundances, and this negatively correlated with bacterial carbohydrate metabolism. Although C. jejuni and Campylobacter coli are prevalent among these infants, the second most abundant Campylobacter species was a new species, which we named "Candidatus Campylobacter infans." Asymptomatic Campylobacter carriers also possess significantly different proportions of specific gut microbes compared to diarrheal cases. These findings provide insight into Campylobacter infections in infants in sub-Saharan Africa and South Asia and help inform strategies aimed at eliminating campylobacteriosis in these areas.

IMPORTANCE Campylobacter is the primary cause of bacterial diarrhea in the United States and can lead to the development of the postinfectious autoimmune neuropathy known as Guillain-Barré syndrome. Also, drug-resistant campylobacters are becoming a serious concern both locally and abroad. In low- and middle-income countries (LMICs), infection with Campylobacter is linked to high rates of morbidity, growth stunting, and mortality in children, and breastfeeding is important for infant nutrition, development, and protection against infectious diseases. In this study, we examined the relationship between breastfeeding and Campylobacter infection and demonstrate the increased selection for C. jejuni and C. coli strains unable to metabolize fucose. We also identify a new Campylobacter species coinfecting these infants with a high prevalence in five of the seven countries in sub-Saharan Africa and South Asia examined. These findings indicate that more detailed studies are needed in LMICs to understand the Campylobacter infection process in order to devise a strategy for eliminating this pathogenic microbe.

KEYWORDS Campylobacter, breastfeeding, GEMS, L-fucose metabolism, "Candidatus Campylobacter infans," gut microbiome

Campylobacter jejuni is one of the major causes of bacterial diarrhea worldwide, and infection leads to a high rate of childhood mortality in low- to middle-income countries (LMICs) (1, 2). Campylobacteriosis is characterized by watery or bloody diarrhea, fever, and abdominal pain and can persist from a few days to several weeks.

Citation Bian X, Garber JM, Cooper KK, Huynh S, Jones J, Mills MK, Rafala D, Kotloff KL, Parker CT, Tennant SM, Miller WG, Szymanski CM. 2020. Campylobacter abundance in breastfed infants and identification of a new species in the Global Enterics Multicenter Study. mSphere 5:e00735-19. https://doi.org/10.1128/mSphere.00735-19.

Editor Vincent B. Young, University of Michigan—Ann Arbor

Copyright © 2020 Bian et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Christine M. Szymanski, cszymans@uga.edu.

Received 7 October 2019
Accepted 9 December 2019
Published 15 January 2020
Occasionally, serious postinfectious sequelae, such as Guillain-Barré syndrome, irritable bowel syndrome, and reactive arthritis, can follow diarrheal disease (3). In LMICs, children under 2 years of age are particularly susceptible to Campylobacter-induced diarrhea, and asymptomatic carriage of Campylobacter species in healthy children is also common (3). C. jejuni can disrupt intestinal tight junctions and induces gut leakage and systemic inflammation (4, 5). Both symptomatic and asymptomatic Campylobacter infections are reported to be associated with growth stunting in children (6, 7).

The Campylobacter genus contains 31 species (http://www.bacterio.net/campylobacter.html), many of which are known pathogens in humans (8). C. jejuni and Campylobacter coli are among the most commonly detected species associated with gastroenteritis, but emerging Campylobacter species, such as Campylobacter upsaliensis, Campylobacter lari, and Campylobacter hyointestinalis, are receiving more attention due to their increasing association with human diseases, likely resulting from improved isolation and detection techniques (8). For example, some Campylobacter spp., including C. hyointestinalis and Campylobacter fetus, are sensitive to antimicrobial agents used in traditional Campylobacter-selective agar and are isolated more frequently using the Cape Town protocol with antibiotic-free blood agar and H2 enrichment (9).

Contaminated foods and water are considered the main sources of Campylobacter infections in LMICs, and the risk of Campylobacter-associated diarrhea in children has been suggested to be reduced by several factors, including breastfeeding (7). In infants <1 year of age, the mother’s milk not only provides nutrition but also supports the establishment of a healthy gut microbiota and the development of a robust immune system (10). Human milk contains antibodies against various pathogens, including Campylobacter, and human milk oligosaccharides (HMOs), particularly fucosyloligosaccharides such as 2’-fucosyllactose, have been reported to inhibit some C. jejuni strains from binding to intestinal epithelial cells and colonizing mouse models (11, 12). Also, HMOs stimulate the growth of beneficial bacteria, such as Bifidobacterium, which provide a variety of health benefits, including competition with enteric pathogens such as Campylobacter (13).

Children who are not breastfed do not receive protective antibodies or HMOs and are thus at a higher risk for infection, particularly diarrheal disease (3, 14). Yet 85% of children had Campylobacter-positive stools by 1 year of age in LMICs where breastfeeding is common (7, 15). Our previous studies have shown that >50% of sequenced C. jejuni and C. coli isolates possess a fuc locus (cj0480c to cj0489) (16) for L-fucose metabolism, providing strains such as C. jejuni NCTC 11168 with a competitive advantage in the colonization of a piglet model for diarrheal disease (16, 17). L-Fucose can be released from fucosylated HMOs by several gut microbes, including Bacteroides and Bifidobacterium species (18–20); thus, it is possible that human milk may actually provide a rich carbon source to promote the growth of Campylobacter strains capable of metabolizing L-fucose. This hypothesis had not been previously explored since C. jejuni and C. coli were considered to be asaccharolytic, relying solely on amino acids and tricarboxylic acid (TCA) cycle intermediates for carbon sources (21). Now, with the discovery that many Campylobacter isolates metabolize L-fucose, together with the observation that free L-fucose levels can reach 4 to 5 mg/g feces in breastfed children (22) and reports that D-glucose is also abundant in feces of breastfed children (22) and that ∼1.7% of sequenced C. jejuni and C. coli strains possess the Entner-Doudoroff (ED) pathway for glucose utilization (23), we sought to examine the relationship between breastfeeding and Campylobacter infections to better understand the process of Campylobacter-induced diarrhea in infants.

To measure the burden and bacterial etiology of diarrheal disease in children under 5 years of age in LMICs, the Global Enterics Multicenter Study (GEMS) was conducted in seven countries in sub-Saharan Africa (The Gambia, Kenya, Mali, and Mozambique) and South Asia (Bangladesh, India, and Pakistan) (24). Liu et al. found that together with other common pathogens, C. jejuni and C. coli were major causes of diarrhea in this age group (2). To examine the relationship between Campylobacter infection and breastfeeding in infants <1 year of age in the GEMS data set at a molecular level, we applied...
molecular techniques to examine the relative abundances of campylobacters and other resident gut microbes in asymptomatic and symptomatic Campylobacter infections. We also screened the C. jejuni and C. coli isolates for their ability to utilize L-fucose and D-glucose and assessed whether this correlated with diarrheal disease. Through these studies, we identified a new Campylobacter species that is present in stool samples of infants from multiple countries and is as prevalent as C. coli.

RESULTS

Data description. Our study included a total of 233 fecal DNA samples from symptomatic and asymptomatic Campylobacter-infected infants <1 year of age that were collected at seven sites (The Gambia, Kenya, Mali, Mozambique, Bangladesh, India, and Pakistan), with infants either exclusively or not breastfed (see Fig. S1 and Table S1 in the supplemental material). Of these 233 samples, 128 were from symptomatic infections (cases) and 105 were from asymptomatic infections (controls); 142 infants were exclusively breastfed, while 91 were not breastfed at the time of stool collection; 110 were 0 to 5 months old, while 123 were 6 to 11 months old; and 111 had moderate-to-severe diarrhea (MSD), while 17 had less-severe diarrhea (LSD).

In 84.12% of the infants, comorbidities with other diarrheal pathogens were identified (Fig. S2), including viruses (astrovirus, norovirus, adenovirus, rotavirus, and sapovirus), other bacteria (Aeromonas, Bacteroides fragilis, Clostridium difficile, Escherichia coli, Helicobacter pylori, Shigella, Salmonella [nontyphoidal], and Vibrio), and parasites (Giardia, Entamoeba, and Cryptosporidium). Comorbidities with viruses were found in 33.48% of the infants, comorbidities with other bacteria were found in 66.95% of the infants, and comorbidities with parasites were found in 22.75% of the infants.

The V6-V8 hypervariable region of the 16S rRNA gene was amplified from 229 samples and sequenced using the Illumina MiSeq platform at the University of Georgia Genomics and Bioinformatics Core; 4 of the 233 samples did not have amplification products and were not sequenced, and all 4 had MSD, with exclusive breastfeeding (2 samples) or no breastfeeding (2 samples). Of the 229 sequenced samples, 140 were from infants who were exclusively breastfed (diarrhea, n=75; no diarrhea, n=65), and 89 were from infants who were not breastfed (diarrhea, n=49; no diarrhea, n=40) at the time of stool collection. A total of 2,899 different amplicon sequence variants (ASVs) were obtained, with a median of 22,244 sequences per sample. Of the 229 samples, a random subset of 67 was amplified using the V4 hypervariable region of the 16S rRNA gene for additional confirmation.

A total of 142 C. jejuni and C. coli strains isolated from the fecal samples (1 isolate per sample) were tested for L-fucose utilization (24, 25). Of these 142 strains, 80 were from symptomatic infants (exclusively breastfed, n=51; nonbreastfed, n=29), and 62 were from asymptomatic infants (exclusively breastfed, n=32; nonbreastfed, n=30).

Compositional variations of fecal microbiota in cases and controls. The Shannon index was calculated to measure the fecal microbial diversity (Fig. 1A) and showed that infants with diarrhea, with or without breastfeeding, had significantly lower fecal microbial diversity (P < 0.01) than asymptomatic infants. Nonbreastfed asymptomatic infants demonstrated the highest fecal diversity (P < 0.001), with fecal diversity within the exclusively breastfed asymptomatic infants being intermediate between the two groups (P < 0.01).

The proportional abundance of taxa comprising each fecal microbiome was determined by sequencing the 16S rRNA V6-V8 hypervariable regions from each sample (Fig. 1B). This analysis showed that Proteobacteria were the most abundant in infants with diarrhea, while the Firmicutes were the most abundant in the controls (Fig. S3A and B). Escherichia and Shigella were the most abundant in all groups regardless of diarrheal status and breastfeeding; however, in infants who were not breastfed, the abundance of Escherichia-Shigella in cases (48.1%) was significantly higher than in controls (17.0%), while in exclusively breastfed infants, the difference was not statistically significant (40.1% in cases and 28.6% in controls) (Table S2). Genera with significant differences between cases and controls are shown in Table S2.
The V4 hypervariable region of the 16S rRNA gene amplifies *Bifidobacterium* effectively (26, 27), and a higher proportion of *Bifidobacterium* in exclusively breastfed than in nonbreastfed infants was observed following sequencing of the V4 hypervariable region (Fig. 1C). The *Bifidobacterium* genus is the most abundant in exclusively breastfed infants, but a higher abundance of *Escherichia-Shigella* was still found in cases (50.01%) than in controls (15.22%) with no breastfeeding (not statistically significant due to the smaller sample size of the V4 data set).

The relative abundance of *Campylobacter* was negatively correlated with several gut microbes, including *Dorea*, *Blautia*, *Klebsiella*, *Erysipelatoclostridium*, *Enterobacter*, *Faecalibacterium*, *Enterococcus*, *Collinsella*, the *Ruminococcus gnavus* group, *Lactococcus*, and *Anaerostipes*, and these gut microbes were positively correlated with each other (Table S3).

**Relative abundance of Campylobacter in symptomatic and asymptomatic infants.** Although *Campylobacter* strains were isolated from all the fecal samples included in our study, 16S rRNA sequencing (V6-V8 regions) of the fecal DNA detected a fraction of them (cases with exclusive breastfeeding, 61/75; controls with exclusive breastfeeding, 31/65; cases with no breastfeeding, 34/49; controls with no breastfeeding, 10/40). As shown in Fig. 1D and E, the 16S rRNA of *Campylobacter* had >0.99 identity value to C. *jejuni*, C. *coli*, C. *lari*, C. *hyointestinalis*, C. *upsaliensis*, and other campylobacters. A greater abundance of *Campylobacter* species was found in cases with breastfeeding (~10%) than in other groups (Fig. 1B). Consistent with results obtained from sequencing the V6-V8 rRNA regions, the results with the V4 regions (Fig. 1C) showed that *Campylobacter* species are also more abundant in cases with breastfeeding (~10%).

**FIG 1** Fecal microbiome in symptomatic and asymptomatic *Campylobacter* infections in infants <1 year of age. (A) Microbial diversities (Shannon index) in different groups. Center line, median; box limits, upper and lower quartiles; whiskers, 1.5× interquartile range; points, outliers. (B) Microbial compositions of fecal samples from cases and controls with breastfeeding (BF) or no breastfeeding (No BF) (V6-V8 of 16S rRNA). P, F, A, and B refer to phyla (P, Proteobacteria; F, Firmicutes; A, Actinobacteria; B, Bacteroidetes). (C) Microbial composition of fecal samples from cases and controls with breastfeeding or no breastfeeding (V4 of 16S rRNA). (D) Proportions of *Campylobacter* species at the individual-child level. Each of the bars represents one individual subject, and different *Campylobacter* species are shown in different colors. (E) Average *Campylobacter* abundance in each group. NS, not statistically significant; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
than in all other groups (not statistically significant because of the smaller V4 sample size).

The relative abundance of *Campylobacter* in the fecal microbiome was highly variable in each group (Fig. 1D). In cases with breastfeeding, the highest abundance of *Campylobacter* was in one child with 83% of the fecal microbiome comprised of one strain with 0.99 identity value to *C. hyointestinalis* subsp. *lawsonii*/uncultured *Campylobacter* by 16S rRNA sequencing. Our results clearly indicate that exclusively breastfed infants with diarrheal symptoms had statistically the highest abundance of campylobacters compared to other groups, including nonbreastfed cases (Fig. 1E). Among nonbreastfed infants, cases had higher levels of *Campylobacter* than controls (Fig. 1E). When comparing controls with and those without breastfeeding, exclusively breastfed infants had higher *Campylobacter* levels than nonbreastfed infants, but the results were not statistically significant (Fig. 1E). Similar trends were found when the data were examined for different sites and ages (Fig. S3C to H).

**Fucose metabolism in *Campylobacter* strains isolated from GEMS.** Despite previous research suggesting that breastfeeding protects against *C. jejuni*-induced diarrhea (11, 28), reports from studies such as GEMS and MAL-ED indicated that a large proportion of breastfed children with diarrhea were *Campylobacter* positive, and our results unexpectedly showed even higher proportions of this genus in breastfed infants compared to other groups, including nonbreastfed cases (Fig. 1E). Among nonbreastfed infants, cases had higher levels of *Campylobacter* than controls (Fig. 1E). When comparing controls with and those without breastfeeding, exclusively breastfed infants had higher *Campylobacter* levels than nonbreastfed infants, but the results were not statistically significant (Fig. 1E). Similar trends were found when the data were examined for different sites and ages (Fig. S3C to H).

![Fig 2](image-url)

**FIG 2** Investigation of the relationship between fucose metabolism and *Campylobacter* infection in GEMS. (A) A PCR screen for the fucose permease gene *fucP* was carried out for all samples, and a representative gel is shown. (B) Verification of the *fucP* colony PCR results to compare the abilities to metabolize fucose and show growth enhancement. Values shown are means (n = 3), and error bars represent 1 standard deviation (*fucP*+ strains are highlighted in boldface type). White, control; black, L-fucose addition. (C) Pie charts comparing the correlations between fucose metabolism and the isolated *Campylobacter* strains. Black, L-fucose-utilizing strains; white, non-L-fucose-utilizing strains. *P* values were determined by chi-squared testing compared to 50%.
mented with l-fucose to confirm that they possessed a functional pathway (Fig. 2B). The results indicate that in nonbreastfed infants, approximately 50% of the strains were fucose utilizing versus nonutilizing (P = 0.5775 and P = 0.4652 for cases and controls, respectively), but in breastfed infants, significantly fewer fucose-utilizing strains (33% and 22% in cases and controls, respectively; P < 0.05) were found (Fig. 2C). Previous studies suggested that there is a negative correlation between the possession of the fucose metabolic locus and the γ-glutamyl transpeptidase (GGT) gene (ggt), which provides the strain the ability to utilize glutamine and glutathione (29). Since glutamine is one of the most abundant free amino acids in breast milk (30), we screened for the ggt gene in all strains and found that only 15 of 137 (11%) screened strains possessed the ggt gene, 12 of 79 (15%) in strains lacking fucP and 3 of 58 (5%) fucP+ strains. For the utilization of α-glucose, 25% of strains were randomly selected and tested in growth assays using limited growth medium supplemented with α-glucose, and none of the tested strains showed enhanced growth in glucose.

A putative new Campylobacter species, “Candidatus Campylobacter infans.”

Multplex PCR of the lipid A biosynthesis gene lpxA was used to confirm the presence of C. jejuni, C. coli, and C. upsaliensis identified by 16S rRNA sequencing (31). However, no molecular identification method was available for C. hyointestinalis, and only one C. hyointestinalis subsp. lawsonii genome was present in GenBank (accession number CP015576), so we sequenced nine additional C. hyointestinalis subsp. lawsonii strains (32), and together with the genome of C. hyointestinalis subsp. hyointestinalis (GenBank accession number NZ_CP015575.1), we designed a primer specific for the C. hyointestinalis lpxA gene of both subspecies to be used for multiplex PCR. The revised lpxA multiplex PCR was performed on the known C. hyointestinalis strains (Fig. S4A) and applied to the GEMS fecal DNA samples that were putatively designated to belong to this species by 16S rRNA sequencing (Fig. S4B). Only samples G9, G21, and G22 have the expected 285-bp product out of the predicted 26 GEMS fecal samples and were confirmed to contain C. hyointestinalis, suggesting that the other campylobacters identified as C. hyointestinalis subsp. lawsonii/uncultured Campylobacter by 16S rRNA sequencing may actually be a new species. One of the 26 infants (G1) (Fig. S4C) had prolonged diarrhea for 9 days, and 83.6% of the fecal microbiome was comprised of this species, with no other Campylobacter species being detected by 16S rRNA analysis, although one C. jejuni strain was isolated from the fecal sample. Metagenomic sequencing of this fecal DNA sample was performed, and assembly of the Illumina reads yielded 6,058 total contigs and 75 contigs identified as Campylobacter, of which 56 were larger than 5,000 bp. Overall, the metagenomic analysis of the fecal sample found the dominant clusters of orthologous groups (COGs) to be associated with functions in metabolism, information storage and processing, and cellular processes and signaling, and in particular, 10.3% of sequence reads were associated with protein metabolism (Fig. S5A and B). While 16S rRNA sequencing found a higher percentage of the fecal microbiome composition to be Campylobacter (83.6%), metagenomic analysis confirmed at the order level (74.3%) and genus level (66.6%) that it was the dominant member of the microbial community (Fig. S5C to E). Furthermore, 33.8% of all the sequence data that were assembled into contigs particularly >10 kb were identified as Campylobacter (Fig. S5F), with an average of 76× coverage for these contigs, which further demonstrated that it was the major genus present in the fecal microbiome and provided sufficient coverage for genome assembly. BLASTP analysis of the 1,476 putative coding sequences identified in the 75 Campylobacter contigs indicated that the Campylobacter species present in this fecal sample was not one of the current validly described Campylobacter taxa; however, 72.8% (1,074/1,476) of the matches showed strong similarity to proteins from members of the C. fetus group (i.e., C. fetus, C. hyointestinalis, C. lawsonii, and C. laniense, and C. iguaniorum). Data from core gene/protein phylogenetic analyses (Fig. 3A and B) and average nucleotide identities (ANI) (Fig. 3C) are consistent with these results, suggesting that the Campylobacter strain in this fecal sample (referred to here as “Candidatus Campylobacter infans”) represents a novel Campylobacter species.
Identification of a new Campylobacter species. (A and B) Sequences of 20 core genes from various Campylobacteraceae or their cognate proteins were concatenated and aligned using CLUSTALX. Included in the alignment were the same 20 concatenated genes or proteins extracted from the metagenomic sequences obtained from a fecal DNA sample containing 83% Campylobacter sequences ("Candidatus Campylobacter infans"). The dendrograms were constructed using the neighbor-joining algorithm and the Kimura two-parameter (gene set) (A) or Poisson (protein set) (B) distance estimation method. Bootstrap values of >75%, generated from 500 replicates, are shown at the nodes. (C) Average nucleotide identity (ANI) of "Candidatus Campylobacter infans" among known related bacteria, including Campylobacter, Sulfurimonas, Arcobacter, Sulfurospirillum, and Helicobacter species.
that is related to, but distinct from, C. fetus, C. hyointestinalis, C. lanienae, and C. iguaniorum.

Using the metagenomic sequencing data, we designed lpxA primers for “Candidatus Campylobacter infans” for comparison with the lpxA primers used for the multiplex PCR that we performed previously and tested all 26 fecal samples that had 16S rRNA predictions closest to C. hyointestinalis subsp. lawsonii/uncultured Campylobacter. The PCR results indicated that 18 of the 26 samples had the expected PCR product, except samples G8, G9, G19, G20, G24, G25, and G26 (Fig. S4C). For further confirmation, specific primers for the “Candidatus Campylobacter infans” full-length atpA gene were designed and used to amplify 20 of the remaining 25 samples. The phylogenetic tree constructed from the aligned amplicon and reference atpA sequences showed that the campylobacters in these 20 samples are very similar to “Candidatus Campylobacter infans” (Fig. 4A). Combining the lpxA and atpA results, 24 of 26 fecal samples were confirmed to contain “Candidatus Campylobacter infans,” and 19 of them were from exclusively breastfed infants, while 5 were from nonbreastfed infants (Fig. 4B), from five out of the seven GEMS countries, including The Gambia, Mali, Mozambique, India, and Pakistan.

As expected, genes encoding pathways for the utilization of amino acids and peptides, including amino acid transporters and peptidases, were identified in the “Candidatus Campylobacter infans” genome. The respiratory enzyme NADH:quinone oxidoreductase (also called complex I) is a major electron source in many bacteria, including C. jejuni (33), but all 14 nuo genes encoding complex I are absent in “Candidatus Campylobacter infans,”
suggesting that it depends on other electron donors, such as hydrogen and formate, unless single-protein NADH dehydrogenases serve the same purpose. Genes required for utilizing hydrogen and formate as electron donors were identified in the metagenome, including those encoding the [Ni-Fe]-type hydrogenase HydABC, a nickel uptake system, and a formate dehydrogenase that can oxidize formate and release protons and electrons. Virulence genes, including those encoding invasion antigens (ciaB and ciaD), the zonula occludens toxin (zot), an outer membrane fibronectin-binding protein (cadF), heavy metal resistance genes, a multidrug efflux pump (cmeABC), and other drug resistance transporters, are potentially part of the “Candidatus Campylobacter infans” genome. Also, “Candidatus Campylobacter infans” may express an S-layer since we detected the presence of an S-layer secretion system (sapDEF), without homologs of the surface layer proteins (sapA and sapB), but other proteins may be involved.

**Prevalence and coinfection of Campylobacter spp. in GEMS.** As expected, since we used a subset of GEMS samples that tested positive for C. jejuni or C. coli, C. jejuni is the most prevalent species among symptomatic and asymptomatic Campylobacter infections, colonizing nearly twice as many infants as the total of all other species (107 colonized with C. jejuni and 68 colonized with other species). However, it is interesting to note that several other Campylobacter species are found, including C. coli (24 infants), “Candidatus Campylobacter infans” (24), and C. upsaliensis (18), and the order of abundance is generally consistent when split into the four groups (Fig. 4B). Among the 131 infants with Campylobacter infections, 36 (27.5%) were coinfected with different Campylobacter species, and among these, 8 (6.1%) were coinfectected with three Campylobacter species (Table S4).

**DISCUSSION**

In LMICs, diarrheal diseases are the second leading cause of mortality in children under 5 years of age, and infection with Campylobacter is one of the major causes of gastroenteritis in these children (1, 2, 7, 34). Previous studies suggest that breastfeeding protects infants from Campylobacter-induced diarrhea by reducing the ingestion of contaminated water/foods and lessening contact with unsanitary surroundings through closer interactions with the mother (7, 12, 28). In addition, breastfeeding increases exposure to fucosylated HMOs, particularly 2’-fucosyllactose in secretor mothers, which is predicted to act as a binding decoy to prevent C. jejuni colonization of the intestine (11). Yet exceedingly high rates of campylobacteriosis are reported among exclusively breastfed infants in LMICs (7). Consistent with these reports, our studies comparing 16S rRNA profiles of fecal DNA isolated from infants in GEMS show a trend of a higher Campylobacter abundance in exclusively breastfed than in non-breastfed infants, leading us to evaluate the metabolic preferences among these isolates. We previously demonstrated that >50% of sequenced C. jejuni isolates possess the fuc locus for L-fucose catabolism (16), and the possession of this pathway provides a competitive colonization advantage in the piglet model of diarrheal disease (17). Since C. jejuni lacks fucosidases, it grows only on fucose-modified gut oligosaccharides in the presence of other gut microbes, such as Bacteroides vulgatus, suggesting a scavenging lifestyle within the intestine (35). Many commensal bacteria in the gut, including Bifidobacterium and Bacteroides, possess fucosidases and are predominant in breastfed infants (18–20), suggesting that breastfeeding may benefit fuc⁺ C. jejuni strains, particularly since fecal levels of free L-fucose can reach milligram amounts in breastfed infants (22).

In this study, we indeed found high levels of Bifidobacterium in breastfed infants, as expected. However, we found that although nonbreastfed infants were colonized with equal proportions of L-fucose-metabolizing and -nonmetabolizing C. jejuni and C. coli strains, the proportion of strains unable to metabolize L-fucose increased significantly in exclusively breastfed infants, although we cannot exclude the possibility that some infants were colonized with multiple strains of these species. This was particularly evident when comparing infants with symptomatic infections, who exhibited 6-fold-higher levels of this organism. Thus, HMOs may indeed function as decoys for Campy-
lobacter fuc⁺ strains, and this may correlate with our recent observation that the fuc locus protein Cj0485 is necessary for Campylobacter L-fucose chemotaxis (16) and new studies in our laboratory comparing chemotaxis and sugar adhesion illustrating differences between strains capable of sugar metabolism and asaccharolytic strains (H. Nothaft, unpublished data). However, these results also suggest that there is a selection for C. jejuni or C. coli strains that are better capable of thriving within the infant gut. In addition to HMOs, breast milk contains high quantities of proteins (especially caseins) and their breakdown products (36), which could promote the growth of campylobacters, particularly since even carbohydrate-utilizing C. jejuni strains prefer amino acids such as serine, glutamate, and aspartate over fucose, indicating the existence of a metabolic hierarchy (35). Thus, a preference for the proteinaceous components in breast milk may make L-fucose or D-glucose utilization irrelevant. Additionally, the quantities of free L-fucose could be smaller than expected if mothers are not secretors or produce smaller quantities of HMOs due to nutrient availability (37, 38). Glutamine is one of the most abundant free amino acids in human milk, and the possession of the γ-glutamyl transpeptidase (GGT) enzyme has been negatively correlated with the presence of the fucose pathway in C. jejuni (29, 30), but only 15% of the isolated C. jejuni and C. coli strains lacking fuc examined in this study contain the ggt gene (lower than the 31% expected) (39), so it is likely that other carbon sources from breast milk fuel the metabolism of the isolated Campylobacter strains. In addition to C. jejuni and C. coli, “Candidatus Campylobacter infants” was also detected nearly three times as frequently in exclusively breastfed infants as in nonbreastfed infants, and the metagenomic data identified pathways for amino acid and peptide utilization, without any obvious clusters for carbohydrate metabolism. Based on the unexpected observation that exclusive breastfeeding increases the Campylobacter abundance in infants <1 year of age, more studies are needed to assess the effect of breast milk on Campylobacter infection, particularly since a recent study in preterm pigs fed human milk oligosaccharides showed increased levels of Proteobacteria dominated by Campylobacter and Helicobacter with longer HMO exposure (40). In particular, targeted epidemiological studies are required to determine whether higher Campylobacter levels are correlated with more severe dysenteric diarrhea. While C. jejuni or C. coli strains were isolated from all infants included in our study, 16S rRNA analysis did not detect Campylobacter in all the corresponding fecal DNA samples. This is consistent with our previous studies on chicken gut microbiome compositions that demonstrated that C. jejuni cannot be detected by 16S rRNA sequencing when <10⁵ CFU per g of cecal content are present (41, 42) and with studies by other groups that found that culture-based methods need to be used for bacteria present at levels below the detection threshold (<10⁶ CFU/g feces) to surpass the “depth bias” of genomic approaches (43, 44).

C. jejuni and C. coli are the two most commonly isolated pathogenic Campylobacter species worldwide (8); however, recently emerging non-C. jejuni/C. coli Campylobacter species have also been associated with gastrointestinal diseases and diarrhea (15). Here, we show that C. jejuni and C. coli are the predominant Campylobacter species in infants <1 year of age in GEMS, and non-C. jejuni/C. coli campylobacters, especially “Candidatus Campylobacter infants” and C. upsaliensis, are also prevalent in this age group. The prevalence of other Campylobacter species may be underestimated in this study since only fecal samples positive for C. jejuni and C. coli were included. Nonetheless, the new species “Candidatus Campylobacter infants” is detected at the same level as C. coli and accounts for approximately 1.6% of the fecal microbiome in exclusively breastfed infants with diarrhea and, in one extreme case, 83% of the total fecal microbiome, which suggests that “Candidatus Campylobacter infants” can be a relevant pathogen in infants. As the third most prevalent Campylobacter species in this study, C. upsaliensis has been previously reported to cause diarrhea in humans (45), and a recent study demonstrated that non-C. jejuni/C. coli species, such as C. hyointestinalis, account for more Campylobacter infections in children <2 years of age in Peru (15, 46). In the present study, coinfection with multiple Campylobacter species is not uncommon, which provides more opportunities for genomic rearrangements between campylo-
bacteria to escape selective pressures and alter virulence properties (47). Taken together, our data indicate that vaccines to prevent Campylobacter infection should not only focus on eliminating C. jejuni and C. coli but also consider other nonthermophilic species, including “Candidatus Campylobacter infans” and C. upsaliensis, for preventing diarrheal disease in infants in LMICs (42, 48). However, among all the infants with Campylobacter infection (both symptomatic and asymptomatic), approximately 16% are infected solely with Campylobacter, and 84% showed comorbidities with other diarrheal pathogens (viruses, other bacteria, and parasites), including 67% of infants diagnosed with Campylobacter-related diarrhea. Many studies have reported that coinfection with multiple intestinal pathogens is common in infants in LMICs, and one proteobacterial infection (such as Escherichia coli, Salmonella, and Campylobacter) increases the host’s susceptibility to other Proteobacteria (i.e., the proteobacterial bloom), so this should be kept in mind when considering the correlations observed in this study (1, 49, 50). Overall, our results indicate that approaches to control the risk of infection by other intestinal pathogens, such as sanitization, water treatment, and vaccination, are important to reduce diarrheal diseases in low-resource settings, but microbial gut compositions may also play a role.

In this study, we demonstrate that infants with diarrhea had the lowest fecal microbial diversity, consistent with data from previous studies that showed that diarrheal disease decreases the diversity of the gut microbiome (51). Diarrhea-free controls had significantly higher gut microbial diversity, which shows that asymptomatic Campylobacter infection does not devastate the gut microbiota as seen in diarrheal cases. When comparing cases and controls, the levels of several different genera were significantly elevated in controls among both exclusively breastfed and nonbreastfed infants, most of which were negatively correlated with Campylobacter yet positively correlated with each other, including Blautia and Dorea, Blautia and Faecalibacterium, and Erysipelato- clostridium and the Ruminococcus gnavus group. Among these genera, Blautia has been observed to have beneficial anti-inflammatory effects in illnesses such as graft-versus-host disease (52); however, other co-occurring bacteria (such as Faecalibacterium prausnitzii) may also protect against diarrhea (53), indicating that more studies need to be done to explore the potential protective roles of other microbes in diarrheal diseases.

Overall, our study points to the need to further explore the contributions of emerging pathogens such as “Candidatus Campylobacter infans” and C. upsaliensis to diarrheal disease in infants in LMICs and the potentially protective roles of intestinal bacteria, particularly those of the Blautia genus, that are associated with asymptomatic Campylobacter carriage. We also report the unexpected observation that a greater Campylobacter abundance is detected in exclusively breastfed infants with diarrheal disease, and further epidemiological studies with corroborating experimental work are warranted. These infants show a reduced incidence of infection with C. jejuni and C. coli fucose-utilizing strains, suggesting that HMOs may indeed function as decoys for fuc+ strains but also select for strains with metabolic properties that render them more capable of thriving in the infant gut. Current studies are focused on the interplay between C. jejuni chemotaxis, binding, and metabolism in exclusively breastfed infants and the development of inexpensive novel intervention and treatment strategies.

MATERIALS AND METHODS

Samples. Fecal DNA samples were obtained from GEMS or the follow-up study GEMS1a, and the study design and methodology were previously described (24). Briefly, GEMS was a prospective case-control study of moderate-to-severe diarrhea (MSD) in children under 5 years of age conducted between 1 December 2007 and 3 March 2011 in seven low- and middle-income countries: The Gambia, Kenya, Mali, Mozambique, Bangladesh, India, and Pakistan. Cases with acute diarrhea were included, each representing a new episode and meeting at least one criterion of MSD (sunken eyes, loss of skin turgor, initiation of intravenous rehydration, dysentery, or hospitalization with diarrhea or dysentery). Controls had no diarrhea in 7 days and were included in the same demographic surveillance system area with cases and matched cases in age, sex, residence, and time. Illness management strategies, including feeding, fluid administration, and breastfeeding practices (no breastfeeding, partly breastfeeding, and exclusively breastfeeding), were queried from the caretakers. A follow-up study called GEMS1a also
enrolled children with MSD as well as children with less-severe diarrhea (LSD) (acute diarrhea without signs of MSD) and matched controls from 31 October 2011 to 14 November 2012, using essentially the same methodology as the one for GEMS. To study the spread of Campylobacter and the effect of breastfeeding on campylobacteriosis, we included DNA samples isolated from stools of cases (both MSD and LSD) and controls under 1 year of age, whose caretakers indicated that they were exclusively breastfed or not breastfed (infants who were still breastfed but also received complementary food were excluded from the analysis), with Campylobacter isolated from the fecal samples using selective Campy-BAP plates for cephalothin-resistant Campylobacter species, including most C. jejuni and C. coli strains, grown at 42°C for 3 days. Subsequently, one single colony per sample was subcultured and used in this study (9).

16S rRNA sequencing and data analysis. The V6-V8 and V4 hypervariable regions of the 16S rRNA gene were amplified from fecal DNA using universal primers described previously (42, 54). The amplification products were cleaned up, normalized, barcoded, and sent to the Georgia Genomics and Bioinformatics Core (GGBC) for sequencing using the Illumina MiSeq PE300 kit. Normalization was based on the double-stranded DNA (dsDNA) concentration detected by using the NanoDrop One® system (Thermo Scientific) and a Qubit 2.0 fluorometer (Thermo Scientific). A total of 12,387,812 sequences were obtained, with a median of 53,166 sequences per sample. DADA2, an open-source software package for modeling and correcting Illumina-sequenced-amplicon errors, was used in QIME2 to filter, trim, dereplicate, and join the yielded paired-end sequences and construct an amplicon sequence variant (ASV) table for further analysis (55–57). The alpha diversity of the fecal microbiome was calculated using the Shannon index in QIME2. Vsearch was used to cluster representative sequences against the SILVA SSU r128 database with 99% identity (58) to known operational taxonomic units (OTUs). Correlation between microbial OTUs was calculated using SparCC, a method to estimate correlation values from compositional data (59).

Fucose permease gene (fucP) and γ-glutamyl transpeptidase gene (ggt) screening and l-fucose/glucose utilization experiments with C. jejuni and C. coli strains. To identify the potential fucose utilization ability of Campylobacter strains isolated in GEMS, we screened for the fucP gene in all GEMS-isolated Campylobacter strains (C. jejuni and C. coli) by colony or genomic DNA PCR using primers designed to amplify the fucP gene of C. jejuni NCTC 11168 (fucP-F/R [CAT GAA AGT GGC TTT TTA CAG/ATT TTT TTC ATC ACC AAG CTT TG]). This primer is compatible with the lpxA and lpxARKK2m primer set was used to verify the presence of C. coli strains (data not shown). To verify that a fucP PCR product corresponded to a strain’s ability to use fucose, we performed growth experiments in a subset of the strains lacking fucP and all fucP+ strains as described previously (14). Briefly, Campylobacter strains were adjusted to an optical density at 600 nm (OD600) of 0.05 and inoculated into 5 ml MEMα (minimum essential medium α; Thermo Fisher Scientific) (with 20 μM iron added) with or without 25 mM L-fucose. The inoculated culture was microaerobically at 37°C for 18 h, and the OD600 was measured using the NanoDrop One® system (Thermo Scientific). Screening for the ggt gene was carried out as previously described (29). To test for β-glucose utilization, we performed growth experiments as described above, using a random subset of 33 strains in DMEM (Dulbecco’s modified Eagle’s medium) without glucose (Thermo Fisher Scientific), and the strains were incubated microaerobically for 48 h. Campylobacter curricularum LMG 24588 was used as the positive control.

Verification of C. jejuni, C. coli, C. upsaliensis, C. lari, and C. hyointestinalis. Representative sequences of 16S rRNA (V6-V8) of Campylobacter classified by Scikit-learn (60) in QIME2 were aligned and classified using SINA with the SILVA SSU r128 database, and bacterial species with a 0.99 minimum identity to the query sequence were obtained (61). A multiplex PCR of the lipid A biosynthesis gene (lpxA) was used to confirm the presence of C. jejuni, C. coli, C. upsaliensis, and C. lari in fecal DNA, as previously described (31). A novel lpxA forward primer was designed here for C. hyointestinalis (lpxA_C этюд) (CAA AGA CGC GGT TTT GGCC CGA TGA AGT CGT G). This primer is compatible with the lpxA primers described previously (31), yielding (in conjunction with the previously described reverse primer) a product of 285 bp. The lpxA_C этюд and lpxARKK2m primer set was used to verify the presence of C. hyointestinalis (both subspecies) in fecal DNA.

Detection of a new Campylobacter species. Illumina reads were initially trimmed to remove adapters and quality filtered (>Q20) using Trimmomatic (v0.39) (62), and human genome contamination was then removed by mapping reads to the human GRCh37/hg19 reference genome with Bowtie2 (v2.1.0) (63). Next, filtered reads were submitted to MG-RAST (64) for gene function prediction and taxonomic abundance determination, while the reads were assembled and the taxonomic abundance was confirmed using the following programs: metaSPAdes (assembly; v3.12.0) (65), Kraken2 (taxonomic abundance; v2.0.8) (66), and Bracken (taxonomic abundance; v2.0.0) (67). The metaSPAdes assembly resulted in 33 contigs identified as Campylobacter, including 24 contigs of >5,000 bp, while an additional assembly with Newbler (v2.6) yielded 75 contigs identified as Campylobacter, including 56 contigs of >5,000 bp. Both sets of assembled Campylobacter contigs from metaSPAdes and Newbler were independently analyzed for completeness and contamination using CheckM software (v1.0.12) (68), which demonstrated that the 33 contigs from metaSPAdes were 94.2% complete, with 4.9% contamination, whereas the 75 contigs from Newbler were 98.3% complete, with only 0.19% contamination (classified as an extremely low level of contamination and within the margin of error for the CheckM software). Therefore, all additional metagenomic Campylobacter analyses were conducted with the contigs from the Newbler assembly. Coding sequences present within the 75-contig set were determined using GeneMark (69). A custom protein database was constructed, which combined the proteomes derived from all currently validated (and fully annotated) Campylobacter and Arcobacter genomes (one to six proteomes
per taxon) present in GenBank. The metagenomic proteome was compared to this custom database through an all-versus-all pairwise BLASTP analysis. Genes within the metagenome were assigned a function based on matches above the minimum requirement of 40% similarity and where the match length was ≥75% of the subject and query protein lengths. The sequences of 20 core genes (aroC, atpA, dnaN, eno, fabH, fr, glnA, groEL, hemB, ileS, lpxA, miaB, mpr, nrdB, pnp, prfA, queA, speA, spoT, and tkt) and their cognate proteins were extracted from the metagenome and 50 Campylobacter, Arcobacter, and Sulfurospirillum genomes. These gene and protein sets were concatenated in the order mentioned above for each genome and aligned using CLUSTALX. Neighbor-joining phylogenetic trees were constructed using MEGA v6 (70): the nucleotide tree was constructed using the Kimura two-parameter model, and the amino acid tree was constructed using the Poisson model. Additionally, the 75 Campylobacter contigs were concatenated and used for an average nucleotide identity (ANI) analysis (71), along with the genomes of 45 Campylobacter, Arcobacter, Sulfurospirillum, and Helicobacter taxa. Using the metagenome sequence, novel lpxA-GEMS [GCAAAAAGCAGTGGCGAGGGTTG] compatible with pslARKK2m) and atpA (atpA-F/R [GTG AGC GCA AAA TTA AAA GCA G/TTA TTC AGC ACT AAA AGT AGC C]) primers were designed and used to verify the presence of this putative new Campylobacter species in the other 25 fecal samples. The atpA sequences were aligned using CLUSTALW, and neighbor-joining phylogenetic trees were constructed with MEGA v7 using the Tamura three-parameter method (72).

Statistics. For analysis of the fecal microbiome, a Kruskal-Wallis test was used to compare alpha diversity values between different groups; differences in the relative abundances of bacterial phyla between groups were calculated by a Kruskal-Wallis H test and corrected by the false discovery rate (FDR) in STAMP (73). For analysis of strains capable of metabolizing fucose, a chi-square test was used to determine if the proportion of samples that can metabolize fucose in both cases and controls significantly differed from 50%.

Data availability. The metagenome containing “Candidatus Campylobacter infusion” can be found in the NCBI database (accession number PRJNA596501). The 16S rRNA sequencing data can also be found in the NCBI database under the following accession numbers: V4 data (PRJNA596502); V6-V8, samples 1-100, data (PRJNA596501); V6-V8, samples 101-233, data (PRJNA596500).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, TIF file, 1.3 MB.
FIG S2, TIF file, 0.8 MB.
FIG S3, TIF file, 1.3 MB.
FIG S4, TIF file, 2 MB.
FIG S5, TIF file, 1.8 MB.
TABLE S1, DOCX file, 0.01 MB.
TABLE S2, DOCX file, 0.01 MB.
TABLE S3, DOCX file, 0.01 MB.
TABLE S4, DOCX file, 0.01 MB.

ACKNOWLEDGMENTS

We thank T. D. Mejias for assistance in the glucose growth experiments. We also thank the Georgia Genomics and Bioinformatics Core (GGBC) for the support in 16S rRNA sequencing.

This work was supported by U.S. Department of Agriculture Agricultural Research Service CRIS project 2030-42000-051-00D.

REFERENCES

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahan SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhattala K, Bikbov B, Bin Abdulhak A, Birbeck G, Blth F, Bolliger I, Boffou S, Buelo C, Burch M, Burney P, Carapetis J, Chen H, Chow D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Cuycaro KC, Couser W, Cowie BC, Criqui MH, Cross M, et al. 2012. Global status report on noncommunicable diseases 2012. World Health Organization, Geneva.
2. Kalk Kitajuger, J.; Kruiswijck, J. J.; van der Hulst, A. T.; Aerts, J. J. J.; van der Graaf, W. J. J.; van der Meer, J. W. M. 2015. The role of Campylobacter jejuni in the pathogenesis of inflammatory bowel disease. Clin Microbiol Rev 2015;28:44–63. https://doi.org/10.1128/CMR.00022-14.
3. Akiba A, Aziz F, Qureshi S, Ramamurthy T, Roberts JH, Saha D, Sow SO, Stroup SE, Sur D, Tamboura B, Taniuchi M, Tennant SM, Toema D, Wu Y, Zaidi A, Nataro JP, Kotloff KL, Levine MM, Houpt ER. 2016. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. Lancet 388:1291–1301. https://doi.org/10.1016/S0140-6736(16)31529-X.
4. Coker AO, Isokpehi RD, Thomas BN, Amisu KO, Obi CL. 2002. Human campylobacteriosis in developing countries. Emerg Infect Dis 8:237–243. https://doi.org/10.3201/081003123.
5. Chen ML, Ge Z, Fox JG, Schauer DB. 2006. Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells by Campylobacter jejuni. Infect Immun 74:6581–6589. https://doi.org/10.1128/IAI.00959-06.
6. Kalischuk LD, Leggett F, Inglis GD. 2010. Campylobacter jejuni induces transcytosis of commensal bacteria across the intestinal epithelium through M-like cells. Gut Pathog 2:14. https://doi.org/10.1186/1757-4749-2-14.
6. Lee G, Pan W, Penarato Yori P, Paredes Oloretegui M, Tilley D, Gregory M, Oberhelman R, Baur R, Chavez CB, Kosek M. 2013. Symptomatic and asymptomatic Campylobacter infections associated with reduced growth in Peruvian children. PLoS Negl Trop Dis 7:e2036. https://doi.org/10.1371/journal.pntd.0002036.

7. Amour C, Gratz J, Mduma E, Svensen E, Rogawski ET, McGrath M, Seidman JC, McCormick BJ, Shrestha S, Samie A, Mahfuz M, Qureshi S, Hotwani A, Babji S, Trigoso DR, Lima AA, Bodhidatta L, Bessong P, Ahmed T, Shakoor S, Kang G, Kosiek M, Guerrant RL, Lang D, Gottlieb M, Houpt ER, Platts-Mills TA, for the Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development Project (MAL-ED) Network Investigators. 2016. Epidemiology and impact of Campylobacter infection in children in 8 low-resource settings: results from the MAL-ED study. Clin Infect Dis 63:1171–1179. https://doi.org/10.1093/cid/ciw542.

8. Kaakoush NO, Cañistro-Rodriguez N, Mitchell HM, Man SM. 2015. Global epidemiology of Campylobacter infection. Clin Microbiol Rev 28:687–720. https://doi.org/10.1128/CMR.00006-15.

9. Jacob P, Mdegele RH, Nonga HE. 2011. Comparison of Cape Town and Skirrow’s Campylobacter isolation protocols in humans and broilers in Morogoro, Tanzania. Trop Anim Health Prod 43:1007–1013. https://doi.org/10.1007/s11250-011-9799-z.

10. Le Doare K, Holder B, Bassett A, Pannaraj PS. 2018. Mother’s milk: a purposeful contribution to the development of the infant microbiota and immunity. Front Immunol 9:361. https://doi.org/10.3389/fimmu.2018.00361.

11. Ruiz-Palacios GM, Cervantes LE, Ramos P, Chavez-Munguia B, Newburg DS. 2003. Campylobacter jejuni binds intestinal H(2)O(2) antigen (Fuc1,2Galb1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem 278:14112–14120. https://doi.org/10.1074/jbc.M301744200.

12. Ruiz-Palacios GM, Calva JJ, Pickering LK, Lopez-Vidal Y, Zaidi AK, Petrov H, Murray EP, Prado V, Vidal R, Steele D, Stockbrome N, Sanesetti P, Glass RI, Robins-Bworn RM, Tauschek M, Svennerholm AM, Berkeley LY, Kotloff K, Levine MM, Nataro JP. 2012. Diagnostic microbiologic methods in the GEMS-1 case/control study. Clin Infect Dis 55(Suppl 4):S294–S302. https://doi.org/10.1093/cid/cis754.

13. Mohamed DE, Arroyo LG, Costa MC, Viel L, Weese JS. 2017. Characterization of fucosylated milk oligosaccharides of healthy and diabetic healthy calves. J Vet Intern Med 31:928–939. https://doi.org/10.1111/jvim.14695.

14. Greussett H, Loepner K, Kunzel S, Baines JF, Rupp J. 2018. Selection of validated hypervariable regions is crucial in 16S-based microbiota studies of the female genital tract. Sci Rep 8:9678. https://doi.org/10.1038/s41598-018-2757-8.

15. Yu ZT, Nanthakumar NN, Newburg DS. 2016. The human milk oligosaccharide 2′-fucosyllactose can influence the development and function of intestinal epithelial cells HEp-2 and IEC-6/37 in human intestinal mucosa. J Nutr 146:1980–1990. https://doi.org/10.3945/jn.116.230706.

16. Muraoka WT, Zhang Q. 2011. Phenotypic and genotypic evidence for L-fucose utilization by Campylobacter jejuni. J Bacteriol 193:1065–1075. https://doi.org/10.1128/JB.01252-10.

17. Zhang Z, Adelman AS, Rai D, Boettcher J, Lünnert S. 2013. Amino acid profiles and the source of infant human milk through lactation: a systematic review. Nutrients 5:4800–4821. https://doi.org/10.3390/nu5094280.

18. Konkel ME, Parker CT, Knibb AL, Ibbott JC, Devane PM, Horn ST, Miller WG, Conner JE, Jaspan HB, Aldrovandi GM, Kuhn L. 2018. Meta-analysis of effects of human milk oligosaccharides on gut microbiota. Adv Nutr 9:719–732. https://doi.org/10.1093/advnut/wny060.

19. Jia Z, Turton J, Sharpe P, Watson AS, Silver LE, O’Hara H, Newbold CI, Walker AM, Smillie W. 2013. The human milk oligosaccharide 2′-fucosyllactose is essential for colonization of the infant gut. MBio 4:137. https://doi.org/10.1128/mBio.01091-13.

20. Garber JM, Nothaft H, Pluvinage B, Stahl M, Bian X, Enriquez A, Butcher JM, Nataro JP. 2012. Diagnostic microbiologic methods in the GEMS-1 case/control study. Clin Infect Dis 55(Suppl 4):S294–S302. https://doi.org/10.1093/cid/cis754.

21. Bian X, Huyhn S, Chapman MH, Szymbanski CM, Parker CT, Miller WG. 2018. Draft genome sequences of nine Campylobacter hyointestinalis subs. Lawsonii strains. Microbial Resour Announc. 7:e0016-18. https://doi.org/10.1128/MRA.01016-18.

22. Weerkrao DR, Olson JW. 2008. The Campylobacter jejuni NADH:ubiquinone oxidoreductase (complex I) utilizes flavodoxin rather than NADH. J Bacteriol 190:915–925. https://doi.org/10.1128/JB.01647-07.

23. Centers for Disease Control and Prevention. 2015. Global diarrhea burden via the Entner-Doudoroff pathway in Campylobacter jejuni. Cell Host Microbe 10:507–514. https://doi.org/10.1016/j.chom.2011.10.007.

24. Ballard O, Morrow AL. 2013. Human milk composition: nutrients and bioactive factors. Pediatr Clin North Am 60:49–74. https://doi.org/10.1016/j.pcn.2012.10.002.

25. Castany-Munoz E, Martín MJ, Prieto PA. 2013. 2′-Fucosyllactose: an abundant, genetically determined soluble glycan present in human milk. Nutr Rev 71:773–789. https://doi.org/10.1111/nur.12079.

26. Smillowitz JT, O’Sullivan A, Barile D, German JB, Lönnerdal B, Slupsky CM. 2015. The human milk oligosaccharide 2′-fucosyllactose is essential for colonization of the infant gut. MBio 4:137. https://doi.org/10.1128/mBio.01091-13.

27. de Haan CPA, Llarena A-K, Revez J, Hänninen M-L. 2012. Association of Campylobacter jejuni metabolic traits with multisecutive sequence types.
42. Nothaft H, Davis B, Lock YY, Perez-Munoz ME, Vinogradov E, Walter J, Rudloff S, Kuntz S, Ostenfeld Rasmussen S, Roggenbuck M, Sprenger N, Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, Littmann ER, Burnham PM, Hendrixson DR. 2018.

43. Lagier JC, Armougom F, Million M, Hugon P, Pagnier I, Robert C, Bittar F, Moyo SJ, Kommedal O, Blomberg B, Hanevik K, Tellevik MG, Maselle SY, Coros C, Szymanski CM. 2016. Engineering the Campylobacter jejuni N-glycan to create an effective chicken vaccine. Sci Rep 6:26511. https://doi.org/10.1038/srep26511.

44. Lagier JC, Armaougm F, Million M, Hugon P, Pagnier I, Robert C, Bittar F, Fournous G, Gimenez G, Maraninchi M, Trape JP, Koonin EV, La Scola B, Raout D. 2012. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect 18:1185–1193. https://doi.org/10.1111/j.1469-0691.2012.

45. Lau JT, Wheeler NJ, Herath I, Lee CH, Collins SM, Berck P, Surette MG. 2016. Capturing the diversity of the human gut microbiota through culture-enriched molecular profiling. Genome Med 8:72. https://doi.org/10.1186/s13073-016-0327-7.

46. Couturier BA, Hale DC, Couturier MR. 2012. Association of Campylobacter upsaliensis with persistent bloody diarrhea. J Clin Microbiol 50:3792–3794. https://doi.org/10.1128/JCM.01807-12.

47. Platts-Mills JA, Liu J, Gratz J, Mduma E, Amour C, Swai N, Tanuciuch M, Begum S, Yori P, Tilley DH, Lee G, Shen Z, Whary MT, Fox JG, McGrath M, Kosek M, Haque R, Houp ERT. 2014. Detection of Campylobacter in stool and determination of significance by culture, enzyme immunosassay, and PCR in developing countries. J Clin Microbiol 52:1074–1080. https://doi.org/10.1128/JCM.02935-13.

48. Burnham PM, Hendrixson DR. 2018. Campylobacter jejuni: collective components promoting a successful enteric lifestyle. Nat Rev Microbiol 16:551–565. https://doi.org/10.1038/s41579-018-0037-9.

49. Moyo SJ, Kommedal O, Blomberg B, Hanevik K, Tellevik MG, Maselle SY, Coros C, Szymanski CM. 2016. Capsule polysaccharide conjugate vaccine against Campylobacter jejuni infection in stool. J Infect Dis 197:435–438. https://doi.org/10.1093/aje/kwx173.

50. Winter SE, Baumer AJ. 2014. Why related bacterial species bloom simultaneously in the gut: principles underlying the “like will to like” concept. Cell Microbiol 16:179–184. https://doi.org/10.1111/cmi.12248.

51. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. 2008. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197:435–438. https://doi.org/10.1086/525047.

52. Jeng RR, Tauro Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, Littmann ER, Ling L, Gobeure AC, Miller LC, Docampo MD, Peled JU, Araña N, Cross JR, Peets TK, Lumish MA, Shono Y, Dudakov JA, Poech H, Hanash AM, Barker JN, Perales MA, Giralt SA, Pamer EG, van den Brink MR. 2015. CheckM: assessing the quality of microbial genomes recovered from isolate, single cells, and metagenomes. Genome Res 25:1043–1055. https://doi.org/10.1101/gr.171219.

53. Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. 2015. VSEARCH: a versatile open source tool for metagenomics. PeerJ 4:e2584. https://doi.org/10.7717/peerj.2584.

54. Friedman J, Alm EJ. 2012. Inferring correlation networks from genomic data. PLoS Comput Biol 8:e1002687. https://doi.org/10.1371/journal.pcbi.1002687.

55. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M, Prettenhofer P, Weiss R, Dubourg V, Vanderplas J. 2011. Scikit-learn: machine learning in Python. J Mach Learn Res 12:2825–2830.

56. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Pales P, Glöckner FO. 2013. The SILVA ribosomal RNA gene database project: improved data processing and Web-based tools. Nucleic Acids Res 41:596–602. https://doi.org/10.1093/nar/gks1219.

57. Bolger AM, Lohse M, Usadel B. 2014. Trimmmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30:2114–2120. https://doi.org/10.1093/bioinformatics/btu170.

58. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods 9:357–359. https://doi.org/10.1038/nmeth.1923.

59. Wilke A, Bischof J, Gerlach W, Glass E, Harrison T, Keegan KP, Paczian T, Trimble WL, Bagchi S, Grama A, Chaterjee S, Meyer F. 2016. The MG-RAST metagenomics database and portal in 2015. Nucleic Acids Res 44:D590–D594. https://doi.org/10.1093/nar/gkv1322.

60. Nusk S, Meleshko D, Korobeynikov A, Pevzner PA. 2017. metaSPAdes: a new versatile metagenomic assembler. Genome Res 27:824–834. https://doi.org/10.1101/gr.213959.116.

61. Wood DE, Salzberg SL. 2014. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol 15:R46. https://doi.org/10.1186/1475-286X-15-46.

62. Lu J, Breitwieser FP, Thielen P, Salzberg SL. 2017. Bracken: estimating species abundance in metagenomic data. PeerJ Comput Sci 3:e104. https://doi.org/10.7717/peerj-cs.104.

63. Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. 2015. CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. Genome Res 25:1043–1055. https://doi.org/10.1101/gr.188520.114.

64. Besemer J, Borodovsky M. 2005. GeneMark: Web software for gene finding in prokaryotes, eukaryotes and viruses. Nucleic Acids Res 33:W451–W454. https://doi.org/10.1093/nar/gki314.

65. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. 2013. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 30:2725–2729. https://doi.org/10.1093/molbev/ms319.

66. Richter M, Rossello-Móra R. 2009. Shifting the genomic gold standard for the prokaryotic species definition. Proc Natl Acad Sci U S A 106:19126–19131. https://doi.org/10.1073/pnas.0906412106.

67. Kumar S, Stecher G, Tamura K. 2016. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Mol Biol Evol 33:1870–1874. https://doi.org/10.1093/molbev/msw054.

68. Parks DH, Tyson GW, Hugenholtz P, Beiko RG. 2014. STAMP: statistical analysis of taxonomic and functional profiles. Bioinformatics 30:3123–3124. https://doi.org/10.1093/bioinformatics/btu494.